Clinical trial
Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving…
NCT00035594 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00035594 |
|---|---|
| Title | Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy |
| Official title | A Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Evaluating the Prophylactic Use of Pegfilgrastim on the Incidence of Febrile Neutropenia in Subjects With Advanced Breast Cancer Treated With Single Agent Docetaxel |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neutropenia |
| Intervention type | Drug |
| Interventions | pegfilgrastim |
| Enrollment | 928 |
| Start date | Feb 1, 2002 |
| Primary completion | Feb 1, 2004 |
| Completion | Jun 1, 2004 |
| First posted | May 6, 2002 |
| Last update posted | May 9, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: